1887

Journal of Medical Microbiology logo

Volume 70, Issue 10

activity of bedaquiline against complex No Access

Abstract

Nontuberculous mycobacteria (NTM) are widespread in the environment and can cause various diseases in humans, especially immunocompromised patients.

Treatment of diseases caused by NTM is a complicated issue, mainly due to the resistance of the pathogen to most antimicrobial agents. Bedaquiline (Bdq) is now widely used for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB).

The main goal of our study was to evaluate the activity of Bdq against complex (MAC), the most common species among NTM.

A total of 166 MAC cultures (124 and 42 ) were studied. The minimum inhibitory concentrations (MICs) of Bdq for and were obtained by twofold serial dilutions in the Middlebrook 7H9 medium. MIC ranges were determined and the MIC, MIC and ECOFF values were obtained.

The MICs in respect of ranged from 0.003 to 1.0 µg ml; those for ranged from 0.003 to 0.5 µg ml. The Bdq MIC and MIC values were found to be 0.015 and 0.12 µg ml respectively, for and 0.007 and 0.06 µg ml, respectively, for . The tentative ECOFF values for and were 0.12 and 0.06 µg ml, respectively.

The main bedaquiline susceptibility parameters for MAC strains isolated in the Moscow region were determined.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): bedaquiline , drug susceptibility testing , M. avium , M. intracellulare and MAC
© 2021 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001439
2021-10-20
2024-04-25
Loading full text...

Full text loading...

References

  1. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R et al. Nontuberculous Mycobacteria Network European Trials group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: An NTM-NET collaborative study. Eur Respir J 2013; 42:1604–1613 [View Article]
     [Google Scholar]
  2. Zignol M, Dara M, Dean AS, Falzon D, Dadu A et al. Drug-resistant tuberculosis in the WHO European region: An analysis of surveillance data. Drug Resist Updat 2013; 16:108–115 [View Article]
     [Google Scholar]
  3. Litvinov VI, Bogorodskaya EM, Borisov SE. Nontuberculous mycobacteria, mycobacterioses Moscow: MNPCBT; 2014
     [Google Scholar]
  4. van der Werf MJ, Ködmön C, Katalinić-Janković V, Kummik T, Soini H et al. Inventory study of non-tuberculous mycobacteria in the European Union. BMC Infect Dis 2014; 14:62 [View Article]
     [Google Scholar]
  5. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. Clin Chest Med 2015; 36:13–34 [View Article]
     [Google Scholar]
  6. Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN et al. Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. Emerg Infect Dis 2017; 23:439–447 [View Article]
     [Google Scholar]
  7. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America Am J Respir Crit Care Med 2007; 175:367–416 [View Article]
     [Google Scholar]
  8. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15:149–161 [View Article]
     [Google Scholar]
  9. Litvinov VI, EYu N, Makarova MV, Krasnova MA, Borisov CE et al. Drug resistance of mycobacteria: Epidemiology. Tuberculosis and socially significant diseases 2019; 3:42–66
     [Google Scholar]
  10. Cowman S, van Ingen J, Griffith DE, Loebinger MR. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J 2019; 54:1900250 [View Article]
     [Google Scholar]
  11. Litvinov V, Makarova M, Galkina K, Khachaturiants E, Krasnova M et al. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using Slomyco test-system. PLoS One 2018; 13:e0203108 [View Article]
     [Google Scholar]
  12. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline atp synthase inhibitor. Antimicrob Agents Chemother 2007; 51:4202–4204 [View Article]
     [Google Scholar]
  13. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S et al. Rates and mechanisms of resistance development in mycobacterium tuberculosis to a novel diarylquinoline atp synthase inhibitor. Antimicrob Agents Chemother 2010; 54:1022–1028 [View Article]
     [Google Scholar]
  14. Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann J-L et al. Bedaquiline inhibits the atp synthase in mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother 2017; 61:e01225-17 [View Article]
     [Google Scholar]
  15. Nguyen TVA, Anthony RM, Bañuls A-L, Nguyen TVA, Vu DH et al. Bedaquiline resistance: Its emergence, mechanism, and prevention. Clin Infect Dis 2018; 66:1625–1630 [View Article]
     [Google Scholar]
  16. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MMPL5 in mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58:2979–2981 [View Article]
     [Google Scholar]
  17. Almeida D, Ioerger T, Tyagi S, Li S-Y, Mdluli K et al. Mutations in Pepq confer low-level resistance to bedaquiline and clofazimine in mycobacterium tuberculosis. Antimicrob Agents Chemother 2016; 60:4590–4599 [View Article]
     [Google Scholar]
  18. Nieto Ramirez LM, Quintero Vargas K, Diaz G. Whole genome sequencing for the analysis of drug resistant strains of mycobacterium tuberculosis: A systematic review for bedaquiline and delamanid. Antibiotics 2020; 9:E133 [View Article]
     [Google Scholar]
  19. Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA et al. Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. J Clin Microbiol 2017; 55:574–584 [View Article]
     [Google Scholar]
  20. Leibert E, Danckers M, Rom WN. New drugs to treat multidrug-resistant tuberculosis: The case for bedaquiline. Ther Clin Risk Manag 2014; 10:597–602 [View Article]
     [Google Scholar]
  21. Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49:1601799 [View Article]
     [Google Scholar]
  22. Nguyen TVA, Cao TBT, Akkerman OW, Tiberi S, Vu DH et al. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Rev Clin Pharmacol 2016; 9:1025–1037 [View Article]
     [Google Scholar]
  23. Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D’Ambrosio L et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017; 49:1700387 [View Article]
     [Google Scholar]
  24. Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report. Eur Respir J 2019; 54:1901522 [View Article]
     [Google Scholar]
  25. Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z et al. Management of drug-resistant tuberculosis. Lancet 2019; 394:953–966 [View Article]
     [Google Scholar]
  26. Philley JV, Wallace RJ, Benwill JL, Taskar V, Brown-Elliott BA et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 2015; 148:499–506 [View Article]
     [Google Scholar]
  27. Vesenbeckh S, Schönfeld N, Krieger D, Bettermann G, Bauer TT et al. Bedaquiline as a potential agent in the treatment of m. Intracellulare and m. Avium infections. Eur Respir J 2017; 49:1601969 [View Article]
     [Google Scholar]
  28. Kwon YS, Koh WJ, Daley CL. Treatment of mycobacterium avium complex pulmonary disease. Tuberc Respir Dis (Seoul) 2019; 82:15–26 [View Article]
     [Google Scholar]
  29. Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother 2019; 74:935–943 [View Article]
     [Google Scholar]
  30. Clinical and Laboratory Standards Institute Susceptibility testing of mycobacteria, nocardiae spp., and other aerobic actinomycetes, 3ed. edn Wayne, PA, USA: 2018
     [Google Scholar]
  31. European Committee on Antimicrobial Susceptibility Testing EUCAST subcommittee on MIC distributions and epidemiological cut-off values (ECOFFs 2014
     [Google Scholar]
  32. Heidarieh P, Mirsaeidi M, Hashemzadeh M, Feizabadi MM, Bostanabad SZ et al. In vitro antimicrobial susceptibility of nontuberculous mycobacteria in Iran. Microb Drug Resist 2016; 22:172–178 [View Article]
     [Google Scholar]
  33. Li G, Pang H, Guo Q, Huang M, Tan Y et al. Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria. Int J Antimicrob Agents 2017; 49:364–374 [View Article]
     [Google Scholar]
  34. Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ Jr. In vitro susceptibility testing of bedaquiline against mycobacterium avium complex. Antimicrob Agents Chemother 2017; 61:e01798-16 [View Article]
     [Google Scholar]
  35. Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother 2017; 61:e02627-16 [View Article]
     [Google Scholar]
  36. Aguilar-Ayala DA, Cnockaert M, André E, Andries K, Gonzalez-Y-Merchand JA et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol 2017; 66:1140–1143 [View Article]
     [Google Scholar]
  37. Martin A, Godino IT, Aguilar-Ayala DA, Mathys V, Lounis N et al. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria. J Med Microbiol 2019; 68:9 [View Article]
     [Google Scholar]
  38. Soni I, De Groote MA, Dasgupta A, Chopra S. Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria. J Med Microbiol 2016; 65:1–8 [View Article]
     [Google Scholar]
  39. Lopez B, Siqueira de Oliveira R, Pinhata JMW, Chimara E, Pacheco Ascencio E et al. Bedaquiline and linezolid mic distributions and epidemiological cut-off values for mycobacterium tuberculosis in the latin american region. J Antimicrob Chemother 2019; 74:373–379 [View Article]
     [Google Scholar]
  40. Kim DH, Jhun BW, Moon SM, Kim S-. Y, Jeon K et al. In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates. Antimicrob Agents Chemother 2019; 63:e00665-19 [View Article]
     [Google Scholar]
  41. Pang Y, Zong Z, Huo F, Jing W, Ma Y et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 2017; 61:e00900-17 [View Article]
     [Google Scholar]
  42. Yu X, Gao X, Li C, Luo J, Wen S et al. In vitro activities of bedaquiline and delamanid against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother 2019; 63:e00031-19 [View Article]
     [Google Scholar]
  43. Keller PM, Hömke R, Ritter C, Valsesia G, Bloemberg GV et al. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in mycobacterium tuberculosis using the MGIT 960 system equipped with tb exist. Antimicrob Agents Chemother 2015; 59:4352–4355 [View Article]
     [Google Scholar]
  44. Torrea G, Coeck N, Desmaretz C, Van De Parre T, Van Poucke T et al. Bedaquiline susceptibility testing of mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother 2015; 70:2300–2305 [View Article]
     [Google Scholar]
  45. Jang JC, Jung YG, Choi J, Jung H, Ryoo S. Bedaquiline susceptibility test for totally drug-resistant tuberculosis mycobacterium tuberculosis. J Microbiol 2017; 55:483–487 [View Article]
     [Google Scholar]
  46. Peretokina IV, Krylova LY, Safonova SG, Ekaterina M, Nosova MV et al. Defining the minimum border value inhibiting concentration of bedaquiline for sensitive clinical strains mycobacterium tuberculosis in different nutrient media. Tuberculosis and socially significant diseases 2018; 3:32–35
     [Google Scholar]
  47. Zhang J, Gou H, Hu X, Hu X, Shang M et al. Status of drug-resistant tuberculosis in China: A systematic review and meta-analysis. Am J Infect Control 2016; 44:671–676 [View Article]
     [Google Scholar]
  48. Vasilieva IA, Belilovsky EM, Borisov SE, Sterlikov SA. Multidrug-resistant tuberculosis of the pathogen in countries of the world and in the Russian Federation. Tuberculosis and lung diseases 2017; 95:5–18
     [Google Scholar]
  49. Dean AS, Cox H, Zignol M. Epidemiology of drug-resistant tuberculosis. Adv Exp Med Biol 2017; 1019:209–220 [View Article]
     [Google Scholar]
  50. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine 2017; 5:291–360 [View Article]
     [Google Scholar]
  51. Zhao X, Wang Y, Pang Y. Antimicrobial susceptibility and molecular characterization of mycobacterium intracellulare in China. Infect Genet Evol 2014; 27:332–338 [View Article]
     [Google Scholar]
  52. Shiau MY, Lee MS, Huang TL, Tsai JN, Chang YH. Mycobacterial prevalence and antibiotic resistance frequency trends in Taiwan of mycobacterial clinical isolates from 2002 to 2014. Medicine (Baltimore) 2016; 95:e2942 [View Article]
     [Google Scholar]
  53. Addo KK, Addo SO, Mensah GI, Mosi L, Bonsu FA. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. BMC Infect Dis 2017; 17:743 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001439
Loading
In vitro activity of bedaquiline against Mycobacterium avium complex
J. Med. Microbiol. 70, 001439 (2021); https://doi.org/10.1099/jmm.0.001439
/content/journal/jmm/10.1099/jmm.0.001439
/content/journal/jmm/10.1099/jmm.0.001439
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error